ImmunGene’s technology empowers monoclonal antibodies targeted to tumor cells by fusing them to immune effector molecules; that is, cytokine, chemokine and co-stimulatory molecules, thereby combining the specificity of antibodies with the potent anti-tumor effects of the immune effector molecule.
ImmunGene CEO Sanjay Khare said that they are pleased that their technology platform of next generation monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders and other diseases is recognised as worthy of this development award.
"This grant will assist us in advancing our antibody-cytokine fusions that have demonstrated targeted toxicity and added tumor benefits over existing therapies through in vitro and in vivo preclinical testing," Khare said.